Literature DB >> 16440408

Changing face of irritable bowel syndrome.

Eamonn M M Quigley.   

Abstract

Recent years have witnessed tremendous progress in our understanding of irritable bowel syndrome (IBS). It is evident that this is a truly global disease associated with significant symptoms and impairments in personal and social functioning for afflicted individuals. Advances in our understanding of gut flora-mucosal interactions, the enteric nervous system and the brain-gut axis have led to substantial progress in the pathogenesis of symptoms in IBS and have provided some hints towards the basic etiology of this disorder, in some subpopulations, at the very least. We look forward to a time when therapy will be addressed to pathophysiology and perhaps, even to primary etiology. In the meantime, a model based on a primary role for intestinal inflammation serves to integrate the various strands, which contribute to the presentation of IBS.

Entities:  

Mesh:

Year:  2006        PMID: 16440408      PMCID: PMC4077493          DOI: 10.3748/wjg.v12.i1.1

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome.

Authors:  H K Bradley; G M Wyatt; C E Bayliss; J O Hunter
Journal:  J Med Microbiol       Date:  1987-02       Impact factor: 2.472

2.  Irritable bowel syndrome--post salmonella infection.

Authors:  M W McKendrick; N W Read
Journal:  J Infect       Date:  1994-07       Impact factor: 6.072

3.  The fecal microbial population in the irritable bowel syndrome.

Authors:  A Balsari; A Ceccarelli; F Dubini; E Fesce; G Poli
Journal:  Microbiologica       Date:  1982-07

4.  Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients.

Authors:  K R Neal; J Hebden; R Spiller
Journal:  BMJ       Date:  1997-03-15

Review 5.  Central nervous system involvement in functional gastrointestinal disorders.

Authors:  Lukas Van Oudenhove; Koen Demyttenaere; Jan Tack; Qasim Aziz
Journal:  Best Pract Res Clin Gastroenterol       Date:  2004-08       Impact factor: 3.043

6.  Risk factors for colon ischemia.

Authors:  Alexander M Walker; Rhonda L Bohn; Clorinda Cali; Suzanne F Cook; Anuli N Ajene; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

7.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

8.  Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial.

Authors:  W Atkinson; T A Sheldon; N Shaath; P J Whorwell
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

9.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

Authors:  H Mertz; B Naliboff; J Munakata; N Niazi; E A Mayer
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Response to intraluminal gas in irritable bowel syndrome. Motility versus perception.

Authors:  J S Galati; D P McKee; E M Quigley
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

View more
  21 in total

Review 1.  What the Gut Can Teach Us About Migraine.

Authors:  Nada Hindiyeh; Sheena K Aurora
Journal:  Curr Pain Headache Rep       Date:  2015-07

2.  All Roads Lead to Rome: Update on Rome III Criteria and New Treatment Options.

Authors:  David Q Shih; Lola Y Kwan
Journal:  Gastroenterol Rep       Date:  2007       Impact factor: 3.651

Review 3.  Close association between intestinal microbiota and irritable bowel syndrome.

Authors:  W-T Fan; C Ding; N-N Xu; S Zong; P Ma; B Gu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-07       Impact factor: 3.267

4.  A novel role for the metabotropic glutamate receptor-7: modulation of faecal water content and colonic electrolyte transport in the mouse.

Authors:  M Julio-Pieper; N P Hyland; J A Bravo; T G Dinan; J F Cryan
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 5.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

6.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

Review 7.  Neuropathophysiology of functional gastrointestinal disorders.

Authors:  Jackie D Wood
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

8.  A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome.

Authors:  Caroline Codling; Liam O'Mahony; Fergus Shanahan; Eamonn M M Quigley; Julian R Marchesi
Journal:  Dig Dis Sci       Date:  2009-08-20       Impact factor: 3.199

9.  Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center.

Authors:  Prashant Singh; Abhishek Agnihotri; Manish K Pathak; Asef Shirazi; Rajeew P Tiwari; V Sreenivas; Rajesh Sagar; Govind K Makharia
Journal:  J Neurogastroenterol Motil       Date:  2012-07-10       Impact factor: 4.924

10.  Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.

Authors:  Lotta Krogius-Kurikka; Anna Lyra; Erja Malinen; Johannes Aarnikunnas; Jarno Tuimala; Lars Paulin; Harri Mäkivuokko; Kajsa Kajander; Airi Palva
Journal:  BMC Gastroenterol       Date:  2009-12-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.